Medhija LLC is a premier American med-tech company and creator of an innovative treatment for non-obstructive azoospermia. The company offers multiple series of products designed to help men with zero sperm count.
United States - August 1, 2023 —
"Dr. Abuelhija presents Prolistem at the European Society of Human Reproductive and Embryonic Medicine (ESHRE 2023)."
Azoospermia is “a condition in which there’s no measurable sperm in a man’s ejaculate” and is one of the leading causes of male infertility. According to data sourced from clevelandclinic.org, it is estimated that approximately 1% of all men and 10-15% of infertile men worldwide struggle with this condition.
Non-obstructive azoospermia refers to zero sperm count and is, fortunately, treatable. While incurable, this condition can be mended by extremely expensive, experimental, and somewhat risky medical procedures. Medhija LLC one of the leading American med-tech companies offers Prolistem, a better alternative – a science-backed treatment designed for men with non obstructive azoospermia.
Prolistem is helmed by Dr. Abuelhija, an internationally renowned scientist who is committed to pushing the boundaries of medical science and creating actionable solutions that modern medicine has not been able to.
Knowing that thousands of men across the globe have low or zero sperm count, Dr. Abuelhija and his team of passionate medical experts and scientists began working on a revolutionary treatment that could significantly increase the odds of successful sperm extraction surgeries.
“Men with non-obstructive azoospermia are often told their condition is incurable and that they will never become a parent. This is devastating for so many men who desperately want to be a father. Prolistem is the next generation of treatment for men with non-obstructive azoospermia. Formulated by experts and patented, our six-month course of supplements could raise your sperm count and improve your chances of a successful sperm-extraction surgery,” said Prolistem’s spokesperson.
Prolistem is a product of years of research, clinical trials, and innovation. Unlike contemporary alternatives, Prolistem uses not one but a variety of cutting-edge materials to craft its azoospermia supplement solutions, with the most prominent being glycyrrhizic acid.
According to Dr. Abuelhija, Prolistem has already shown remarkable success across the board:
“Our innovative course has yielded impressive success rates, with 48% of patients achieving successful outcomes. Among them, 23% of patients had sperm detected in their semen while 25% of patients had successful surgical sperm extractions following the completion of Prolistem course,” the firm’s spokesperson continued.
Prolistem’s formula features glycyrrhizic acid sourced from a special type of licorice to suppress 17-beta enzymes, and consequentially suppress testosterone levels. This way, Prolistem promotes better spermatogenesis. The primary purpose of using Prolistem is to restore germ cell development and ultimately restore the patient’s fertility.
Prolistem has been widely hailed as the only fertility supplement that tackles non-obstructive azoospermia. While the majority of contemporary alternatives target a variety of other fertility-related issues, Prolistem’s laser focus on suppressing testosterone and boosting spermatogenesis is showing incomparably better results.
More information about Prolistem is available on the company’s official website.
Contact Info:
Name: Prolistem Team
Email: Send Email
Organization: MedHija LLC
Phone: 8452336550
Website: http://www.prolistem.com/
Release ID: 89103608
In case of detection of errors, concerns, or irregularities in the content provided in this press release, or if there is a need for a press release takedown, we strongly encourage you to reach out promptly by contacting error@releasecontact.com. Our efficient team will be at your disposal for immediate assistance within 8 hours – resolving identified issues diligently or guiding you through the removal process. We take great pride in delivering reliable and precise information to our valued readers.
